Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002316 · ClinicalTrials.gov registry record · Phase 1
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002316: Completed Phase 1 study, sponsored by Alkermes.
NCT00002316 is a Phase 1 study that has completed, run by Alkermes. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002316, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV infection and cryptococcal meningitis and to determine the MTD of the drug. To evaluate the pharmacokinetics, including cerebrospinal fluid (CSF) penetration, of amphotericin B when administered with RMP-7.
Interventions
- DRUG Amphotericin B
- DRUG Lobradimil
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002316 record still lists
NCT00002316 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Amphotericin B is the first listed.
NCT00002316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002316 about?
NCT00002316 is a clinical study titled "The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis". To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV infection and cryptococcal meningitis and to determine the MTD of the drug. To evaluate the pharmacokinetics, including cerebrospinal fluid (CSF) penetration, of amphotericin B when administered with RMP-7.
What is the current status of trial NCT00002316?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002316?
The interventions under investigation include: Amphotericin B (DRUG), Lobradimil (DRUG).
Who is sponsoring clinical trial NCT00002316?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.